(ANSA) - ROME, MARCH 18 - According to the clinical commission of the AstraZeneca email vaccine "it cannot be associated with an increase in thrombosis events".
Emer Cook, director of EMA, said this at a press conference.
"We will launch further insights to understand more" regarding the rare adverse events reported after vaccination with AstraZeneca.
Thrombosis cases after administration of the AstraZeneca vaccine are "lower" than those occurring among the unvaccinated population.
This was stated by Sabien Straus, president of the Prac (Pharmacovigilance Commission), in the press conference of the EMA.
(HANDLE).